

Literatur

- (1) Willers C, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Borgström F, Kanis JA; SCOPE review panel of the IOF. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022 Jan 26;17(1):23. <https://doi.org/10.1007/s11657-021-00969-8>
- (2) Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008 Mar;93(3):861-8. <https://doi.org/10.1210/jc.2007-1876>
- (3) MSD Manuals. Osteoporose. [Internet]. Kenilworth (NJ): Merck & Co., Inc.; [abgerufen am 25. August 2025]. Verfügbar unter: <https://www.msdmanuals.com/de/profi/erkrankungendes-rheumatischen-formenkreises-und-des-bewegungsapparats/osteoporose/osteoporose>
- (4) Lorentzon M, Johansson H, Harvey NC, McCloskey EV, Vandenput L, Kanis JA, et al. Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability – results from the Women's Health Initiative hormone therapy trials. Osteoporos Int. 2022;33(11):2297-305. <https://doi.org/10.1007/s00198-022-06483-y>
- (5) World Health Organization (1994). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group [Tagung in Rom vom 22. bis 25. Juni 1992]. World Health Organization. Verfügbar unter: <https://iris.who.int/handle/10665/39142>
- (6) Lippuner K, Johansson H, Kanis JA, Rizzoli R. Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int. 2009 Jul;20(7):1131-40. <https://doi.org/10.1007/s00198-008-0779-8>
- (7) Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029-49. <https://doi.org/10.2147/TCRM.S138000>
- (8) Fischer V, Haffner-Luntzer M, Amling M, Ignatius A. Calcium and vitamin D in bone fracture healing and post-traumatic bone turnover. Eur Cell Mater. 2018 Nov 29;35:365-85. <https://doi.org/10.22203/eCM.v035a25>

- (9) Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. *Ther Adv Musculoskelet Dis*. 2014 Oct;6(5):185-202. <https://doi.org/10.1177/1759720X14546350>
- (10) Dachverband Osteologie e.V. DVO-Leitlinie Osteoporose: Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern ab dem 50. Lebensjahr – Leitlinienreport Version 2023. Berlin: DVO; 2023. Verfügbar unter: <https://leitlinien.dv-osteologie.org>
- (11) Eisenhauer A, Sönnichsen S, Hastuti A, Shroff R, Heuser A, Kolevica A, et al. Monitoring denosumab therapy using the calcium isotope marker (CIM) technology. *Bone*. 2025 Sep;198:117522. <https://doi.org/10.1016/j.bone.2025.117522>
- (12) Eisenhauer A, Hastuti A, Heuser A, Kolevica A, Brandt B, Shroff R, et al. Calcium isotope composition in serum and urine for the assessment of bone mineral balance (BMB) – The Osteolabs post-market follow-up study. *Bone*. 2024;177:116580. <https://doi.org/10.1016/j.bone.2024.117210>
- (13) Eisenhauer A, Müller M, Heuser A, Kolevica A, Glüer CC, Both M, et al. Calcium isotope ratios in blood and urine: a new biomarker for the diagnosis of osteoporosis. *Bone Rep*. 2019 Dec;11:100220. <https://doi.org/10.1016/j.bonr.2019.100200>
- (14) Morgan JL, Skulan JL, Gordon GW, Romaniello SJ, Smith SM, Anbar AD. Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes. *Proc Natl Acad Sci U S A*. 2012 Jun 19;109(25):9989-94. <https://doi.org/10.1073/pnas.1119587109>
- (15) Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD. Low bone mineral density and fracture burden in postmenopausal women. *CMAJ*. 2007 Sep 11;177(6):575-80. <https://doi.org/10.1503/cmaj.070234>